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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYGlucagon-like peptide 1 (GLP-1) plays an important role in regulating bone remodeling, andGLP-1 receptor agonist shows a positive rela-
tionship with osteoblast activity. However, GLP-1 receptor is not found in osteoblast, and the mechanism of GLP-1 receptor agonist on
regulating bone remodeling is unclear. Here, we show that the GLP-1 receptor agonist exendin-4 (Ex-4) promoted bone formation and
increased bone mass and quality in a rat unloading-induced bone loss model. These functions were accompanied by an increase in oste-
oblast number and serumbone formationmarkers, while the adipocyte numberwas decreased. Furthermore, GLP-1 receptorwas detected
in bone marrow stromal cells (BMSCs), but not in osteoblast. Activation of GLP-1 receptor by Ex-4 promoted the osteogenic differenti-
ation and inhibited BMSCadipogenic differentiation through regulating PKA/b-catenin and PKA/PI3K/AKT/GSK3b signaling. These find-
ings reveal that GLP-1 receptor regulates BMSC osteogenic differentiation and provide a molecular basis for therapeutic potential of
GLP-1 against osteoporosis.INTRODUCTION
Osteoporosis is the most common metabolic bone disease,
and it affects many people such as the elderly, long-term
bed-ridden patients, astronauts, and persons living seden-
tary lifestyles (Armbrecht et al., 2011; Edwards et al.,
2015; Lau and Guo, 2011; Rachner et al., 2011). Disuse or
unloading-induced osteoporosis leads to an insufficient
number of osteoblasts or a reduction in their function.
These effects are well known as some of the main causes
in the pathogenesis of osteoporosis (Kondo et al., 2011;
Nakamura et al., 2013). Therefore, drugs that induce the
differentiation and proliferation of osteoblasts, thus pro-
moting bone formation, may represent a strategy for the
prevention and treatment of osteoporosis, which, how-
ever, still remains an unmet medical need.
Recent reports showed that glucagon-like peptide-1
(GLP-1), a gastrointestinal hormone whose release is stim-
ulated by ingestion, acts as an important modulator of
bone growth and remodeling (Kim et al., 2013; Yamada
et al., 2008). In addition, our previous investigation sug-
gested that exendin-4 (Ex-4), a peptide analog of GLP-1,
induced bone formation by osteoblast activation in old
ovariectomized (OVX) rats (Ma et al., 2013), raising a new
question regarding the downstream molecular mecha-
nisms underlying the osteogenic effect. The elucidation
of this effect would provide insight into the pathophysi-Stemology of osteoporosis and the pharmacological properties
of GLP-1 and its analogs.
GLP-1 and its analogs exert their physiological and phar-
macological effects mainly via the GLP-1 receptor
(GLP-1R). However, at present GLP-1R expression in osteo-
blastshasnot beenclearly confirmed.Many studies reported
that GLP-1R was not expressed in primary osteoblasts and
Saos-2 cells (Aoyama et al., 2014; Bollag et al., 2000; Yamada
et al., 2008). Other research reported that GLP-1R was
expressed in young osteoblasts derived from TE-85 and
MG-63, but not in mature osteoblasts derived from Saos-2
osteosarcoma cell line (Pacheco-Pantoja et al., 2011). At
the same time, GLP-1R was also detected during osteogenic
differentiation of human adipose-derived stem cells (Jeon
et al., 2014). In our previous work, we found that Ex-4 oste-
ogenic action inOVXratswas a consequenceof thedifferen-
tiation of bone marrow stromal cells (BMSCs) through the
promotion of osteogenesis and a simultaneous suppression
of adipogenesis (Ma et al., 2013). Moreover, additional
experimental analyses demonstrate the presence of the
GLP-1R mRNA and protein in human BMSCs (Sanz et al.,
2010). These lines of evidence provide a strong hint that
BMSCs might be a cell target that mediates the osteogenic
effect of GLP-1 and its analogs.
BMSCs are potential stem cells with the ability to differ-
entiate into osteoblasts or adipocytes depending on the sit-
uation (Pittenger et al., 1999). Indeed, several moleculesCell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authors 579
possess a role in regulating the differentiation of BMSCs
(D’Alimonte et al., 2013; Shui et al., 2003; Yang et al.,
2012). The Wnt/b-catenin signaling pathway appears to
be of particular importance, since its activation promotes
BMSCs differentiation into osteoblast cells while suppress-
ing their adipogenic potential (Liu et al., 2009), which is
highly similar to the effect of GLP-1 and its analogs. In
particular, b-catenin stabilization and induction of its
translocation into the nucleus play an important role in
promoting BMSC osteogenic differentiation. Furthermore,
previous studies suggested that b-cateninmayhave interac-
tive effects on the cyclic AMP (cAMP) signaling pathway
(Hino et al., 2005; Ke et al., 2012). The enhancement of
cAMP signaling was reported to facilitate b-catenin
signaling in many types of cells (Jiang et al., 2013; Liu
and Habener, 2008; Zhang et al., 2014). Therefore, since
GLP-1Rs are G-protein-coupled receptors able to induce
intracellular cAMP formation and trigger the cAMP-protein
kinase A (PKA) signaling pathway when activated (Hayes
et al., 2011; Holst, 2007), we hypothesized that Ex-4 might
exert its osteoblast activation effect by inducing cAMP and
b-catenin signaling in BMSCs.
To prove our hypothesis, we investigated the effect of
Ex-4 on BMSC differentiation and bone formation both
in vitro and in vivo. With the induction of disuse osteopo-
rosis in tail-suspended rats, our results showed that GLP-1R
activation improved osteoporosis and promoted BMSC
osteogenic potential through the regulation of the PKA/
b-catenin signaling pathway. These results advocate
GLP-1 and its analogs as rather promising drugs against
osteoporosis.RESULTS
GLP-1R Agonist Ex-4 Increased Bone Mass and Bone
Strength in Hindlimb-Unloading-Induced Bone
Loss Rats
To elucidate the role of GLP-1R in the control of skeletal ho-
meostasis, we analyzed the bone structural characteristics
after GLP-1R agonist Ex-4 treatment in hindlimb-un-
loading rats. After mechanical unloading for 4 weeks,
hindlimb-unloading rats exhibited a lower bone mineral
density (BMD) and fewer, thinner, andmore broken trabec-
ular bones in femur and vertebra compared with the rats in
the normal control group not subjected to hindlimb un-
loading as well as any other treatment, as displayed by
the microcomputed tomography (microCT) scans of femur
and vertebra. However, the trabecular architecture was
remarkably improved in the Ex-4-treated rats belonging
to the hindlimb-unloading treatment group compared
with the rats in the hindlimb-unloading control group
treated with the vehicle. The BMD and bone volume to tis-580 Stem Cell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authosue volume ratio in the rats of the hindlimb-unloading
treatment group were remarkably higher than those in
the rats of the hindlimb-unloading control group (Figures
1A–1C). The trabecular number, trabecular thickness,
trabecular spacing, and structure model index were also
remarkably improved in the rats of the hindlimb-unload-
ing treatment group (Figures 1D–1G).
Consistently, the results of the three-point bending test
in the femur samples and compression analysis in the
vertebra samples showed that the biomechanical proper-
ties such as maximum load, stiffness, stress, and Young’s
modulus were decreased after mechanical unloading in
the rats of the hindlimb-unloading control group. All pa-
rameters were significantly enhanced after Ex-4 treatment
(Figures 1H–1K). Thus, Ex-4 administration can prevent
the bone loss and architectural deterioration caused byme-
chanical unloading in rats.
Ex-4 Stimulated Bone Formation and Increased the
Number of Osteoblasts
To further assess how Ex-4 ameliorated the unloading-
induced bone loss, we examined the bone formation-
related parameters by bone histomorphometry analysis.
In agreement with the imaging studies, dynamic histo-
morphometric analysis of the femoral bone sections
from the hindlimb-unloading control group revealed a
significant decrease in the bone mineral apposition rate
(MAR), bone mineralizing surface when expressed per
bone surface (MS/BS), and bone formation rate per bone
surface (BFR/BS), determined by double calcein labeling,
compared with the normal control group. However,
MAR, BFR/BS, and MS/BS were significantly increased
after Ex-4 treatment (Figures 2A–2D). In addition, osteo-
calcin, bone alkaline phosphatase, and N-terminal pro-
peptide concentrations, biomarkers of bone formation in
serum, were significantly reduced in the rats of the hin-
dlimb-unloading control group compared with the
normal control rats. The concentrations of the above
biomarkers were significantly increased in the rats of the
hindlimb-unloading treatment group compared with the
hindlimb-unloading control group (Figures 2E–2G). More-
over, consistent with the reduction of bone formation
markers, the number of osteoblasts, as well as the dy-
namic measures of bone formation, was reduced in the
trabecular bone of the hindlimb-unloading control group,
while Ex-4 remarkably increased the number of osteo-
blasts (Figures 2H and 2I). Interestingly, we also found
that the number of adipocytes in the bone marrow of
the hindlimb-unloading control group was increased
compared with the normal control rats, while this num-
ber was dramatically decreased after Ex-4 treatment
compared with the hindlimb-unloading control group
(Figures 2J and 2K).rs
Figure 1. GLP-1R Activation by Ex-4 Increased Bone Mass and Ameliorated Osteoporosis in Hindlimb-Unloading Rats
(A) MicroCT representative three-dimensional reconstructive images of a trabecular bone from the distal femur metaphyses and L4
vertebrae of normal control rats (Con) and hindlimb-unloaded rats treated with vehicle (H-U) or Ex-4.
(B–G) MicroCT analysis of distal femur metaphyses and L4 vertebrae from different rat groups (n = 6 independent samples/group). BMD,
bone mineral density; BV/TV, bone volume/total volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular sepa-
ration; SMI, structure model index.
(H–K) Ex-4 improved bone biomechanical properties in femur diaphysis and L3 vertebrae from different rat groups (n = 12 independent
samples/group). Maximum load (N) of the bone before crushing; stiffness (N/mm), the slope of the linear region; maximum stress (MPa),
the maximum load per cross-sectional area; Young’s modulus (GPa), maximum slope of the stress-strain curve.
Bars represent mean and SD. **p < 0.01 versus normal control rats (Con) and #p < 0.05, ##p < 0.01 versus hindlimb-unloaded rats (H-U) by
one-way ANOVA followed by a Student-Newman-Keuls t test.Ex-4 Promoted Osteoblasts and Suppressed BMSC
Adipocyte Differentiation
Although our study indicated that Ex-4 exhibited a bone
anabolic effect, there are no reports attesting the presence
of GLP-1Rs in osteoblasts. Thus, GLP-1 cannot exert a
direct effect on osteoblast differentiation. In addition,
since GLP-1R is expressed in human BMSCs, in our
attempt to investigate the mechanisms underlying GLP-
1R-mediated bone anabolic effect we evaluated whether
rat BMSCs expressed GLP-1R using real-time PCR, western
blotting, and immunocytochemistry. Our results showed
that GLP-1R was not expressed in primary osteoblasts
cultured in osteogenesis induction medium (OIM) for
4 weeks, but was expressed in both rat insulinoma cell
line (INS-1, GLP-1R-positive cell) and rat BMSCs (Figures
2L–2N). To evaluate the potential of BMSCs to differen-
tiate into mature matrix-producing osteoblasts after Ex-4
treatment, we cultured BMSCs in OIM or in adipogenesis
induction medium (AIM). Our results showed that Ex-4
significantly increased the expression of osteoblast differ-
entiation-related genes and proteins, such as Runx2/
RUNX2 at day 7 after Ex-4 treatment, Sp7/osterix at day
10 (Figures 3A, 3B, 3D, and 3E), and impaired mineralStemdeposition of cells at day 28 (Figures 3J and 3L). Ex-4
also increased the expression of mature matrix-producing
osteoblast marker genes such as Balp and Bglap by real-
time PCR at day 14 or day 28 after Ex-4 treatment, res-
pectively (Figures 3G and 3H). In contrast, Ex-4 led to
decreases in the mRNA and protein expression of the
peroxisome proliferator-activated receptor g (PPARg) at
day 3 (Figures 3C and 3F), as well as decreases in the lipo-
protein lipase mRNA (Lpl) expression at day 14, and
consequent lipid production in the differentiated adipo-
cytes, as shown by oil red O at day 21 (Figures 3I, 3K,
and 3M). These data suggested that Ex-4 played an impor-
tant role in stimulating BMSCs osteoblast differentiation
and inhibiting their differentiation into adipocytes.
Furthermore, the GLP-1R antagonist exendin(9–39)
[Ex(9–39)] attenuated the Ex-4 effect of improving osteo-
genesis and inhibiting adipogenesis of BMSCs (Figures
3A–3M), indicating that GLP-1R might play an important
role in regulating BMSC differentiation. To further deter-
mine whether Ex-4 mediated BMSC differentiation
through the activation of GLP-1Rs, we downregulated
BMSC GLP-1R via lentiviral small hairpin RNA (shRNA)
infection, and the cells were subsequently treated withCell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authors 581
Figure 2. GLP-1R Activation by Ex-4
Increased Bone Formation and Osteoblast
Number
(A) Images showing the new bone formation
of the femur trabecular bone sections of rats
treated with vehicle (H-U) or Ex-4. Scale bar,
10 mm.
(B–D) Dynamic bone histomorphometric
parameters in the femur trabecular bone
sections (n = 6 independent samples/group).
MAR, mineral apposition rate; MS/BS,
mineralizing surface/bone surface; BFR/BS,
bone formation rates/bone surface area.
(E–G) Bone formation markers: osteocalcin
(OCN), bone alkaline phosphatase (BALP),
and N-terminal propeptide (PINP), in the
serum of different rat groups (n = 12 inde-
pendent samples/group).
(H and I) H&E-stained osteoblasts (yellow
arrows) from rats’ tibial sections (H). The
number of osteoblasts (N.Ob) per millimeter
of trabecular bone surface (BS) was evaluated
(n = 6 independent samples/group) (I). Scale
bar, 100 mm.
(J and K) Toluidine blue-stained adipocytes
(red arrows) from rats’ tibial sections (J). The
number of adipocytes (N.Adipocyte) per
square centimeter was evaluated (n = 6 in-
dependent samples/group) (K). Scale bar,
100 mm.
(L–N) GLP-1R in primary osteoblast, rat INS-1
(GLP-1R positive cell), and BMSCs by RT-PCR
(L), western blot (M), and immunofluores-
cence confocal microscopy (N) with GLP-1R
antibody (green fluorescence) and Hoechst
(blue fluorescence). Scale bar, 50 mm.
Bars represent mean and SD. **p < 0.01
versus normal control rats (Con) and #p <
0.05, ##p < 0.01 versus hindlimb-unloaded
rats (H-U) by one-way ANOVA followed by a
Student-Newman-Keuls t test.10 nM Ex-4. Our results showed that the effect of Ex-4 on
enhancing the expression of Runx2, Pparg, Balp, and lpl
was abolished when BMSCs were infected with
shRNA15015, shRNA15016, or shRNA15017 (Figure S1).
Moreover, GLP-1R downregulation by shRNA15016
reduced the effect of Ex-4 on the promotion of genes
and protein expression related to osteoblast differen-
tiation, and abolished Ex-4-promoted mineralization of
differentiated osteoblasts. In contrast, the inhibitory ef-
fects of Ex-4 on adipocyte differentiation were reversed
by GLP-1R downregulation (Figures 3A–3M). These data582 Stem Cell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authoindicated that GLP-1R receptor was involved in BMSC
osteoblast differentiation while it inhibited their differen-
tiation into adipocytes.
Ex-4 Effect on b-Catenin in BMSCs
Since the canonical Wnt/b-catenin signaling pathway
plays a pivotal role in the modulation of BMSC differenti-
ation, we investigated whether it was involved in the ef-
fect of Ex-4 on BMSC differentiation through GLP-1R.
Our western blot results showed that Ex-4 treatment
increased the accumulation of b-catenin in the cytoplasmrs
Figure 3. GLP-1R Activation Promoted
BMSC Osteoblast Differentiation and Sup-
pressed their Differentiation into Adipo-
cytes
(A–C) Real-time PCR of Runx2, Sp7, and Pparg
mRNA in BMSCs subjected to different treat-
ments. Runx2 and Sp7 mRNA expression in
BMSCs cultured in OIM were examined at days
7 and 10 after treatment, respectively. Pparg
mRNA expression in BMSCs cultured in AIM
was examined at day 3 after treatment.
(D–F) Western blot of RUNX2, osterix, and
PPARg proteins in BMSCs subjected to
different treatments. RUNX2 and osterix
protein expression in BMSCs cultured in
OIM were examined at days 7 and 10 after
treatment, respectively. PPARg protein
expression in BMSCs cultured in AIM was
examined at day 3 after treatment. Bars
represent the protein quantitative data
normalized by b-actin.
(G–I) Real-time PCR of Balp, Bglap, and Lpl
mRNA in BMSCs subjected to different treat-
ments. Balp and Bglap mRNA expression in
BMSCs cultured in OIM were examined at days
14 and 28 after treatment, respectively. Lpl
mRNA expression in BMSCs cultured in AIM
was examined at day 14 after treatment.
(J and L) Mineralized matrix in BMSCs and its
quantification. BMSCs were cultured in OIM
and were stained with alizarin red S at day 28
after treatment. Scale bar, 3mm.
(K and M) Lipid content in BMSCs and its
quantification. BMSCs were cultured in AIM
and were stained with oil red O at day 21 after
treatment. Scale bar, 50 mm.
BMSCs were treated with vehicle (Con), 10 nM Ex-4 alone (Ex-4), or pretreated with 100 nM Ex(9–39) for 1 hr followed by 10 nM Ex-4
treatment (Ex-4+Ex(9–39)); the GLP-1R silenced BMSCs by sh-glp-1r were treated with 10 nM Ex-4 alone (sh-glp-1r + Ex-4) in OIM or AIM.
Data are expressed as mean ± SD from three independent experiments. **p < 0.01 versus vehicle treatment (Con), #p < 0.05, ##p < 0.01
versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.and enhanced the translocation of b-catenin in the nu-
cleus in a time-dependent manner (Figures 4A–4C). These
data were confirmed by immunofluorescence staining
(Figure S2). Since the stable cytosolic b-catenin possesses
the ability to transfer into the nucleus and bind with
the transcription factor 7-like 2 (TCF7L2) to activate the
expression of Wnt signaling target genes, including osteo-
genic regulatory genes, we evaluated the TCF7L2 mRNA
expression level. Ex-4 upregulated TCF7L2 mRNA expres-
sion compared with control (Figure 4D). The block or
downregulation of GLP-1R by Ex(9–39) or shRNA, respec-
tively, inhibited the induction of TCF7L2 induced by Ex-4
(Figure 4D). In addition, the levels of the osteogenic
regulators Runx2 and osterix were increased by Ex-4, but
were decreased when BMSCs were pretreated withStemEx(9–39) or shRNA-GLP-1R (Figures 3D and 3E). These re-
sults suggested that GLP-1R induced b-catenin nuclear
translocation, and improved the expression of TCF7L2
and osteogenic regulators.
Ex-4 Stimulated b-Catenin Nuclear Translocation
through PKA/b-Catenin and PKA/PI3K/AKT/GSK3b
Signaling Pathways
To further elucidate how GLP-1R interacted with the ca-
nonical Wnt/b-catenin signaling pathway, we investigated
the downstream effectors used by GLP-1R and the Wnt/
b-catenin system in BMSCs. Our results showed that the
activation of GLP-1R by Ex-4 significantly enhanced the
level of the PKA catalytic subunit (PKAc), which is associ-
ated with the increased phosphorylation of Ser-675 in theCell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authors 583
Figure 4. GLP-1R Activation Induced b-catenin Nuclear Trans-
location in BMSCs
(A) Western blot of cytoplasmic (C-b-cat) and nuclear b-catenin
(N-b-cat) proteins in BMSCs stimulated by 10 nM Ex-4 at the
indicated times.
(B and C) Bars represent the quantification of the cytoplasmic and
nuclear b-catenin protein normalized by b-actin or histone H3.1.
(D) Real-time PCR of TCF7L2 mRNA in BMSCs subjected to different
treatments. BMSCs were cultured in OIM.
Data are expressed as mean ± SD from three independent experi-
ments. **p < 0.01 versus vehicle treatment (Con), ##p < 0.01 versus
Ex-4 treatment by one-way ANOVA followed by a Student-Newman-
Keuls t test.
584 Stem Cell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authocytosolic b-catenin and accumulation of b-catenin in the
nucleus. Forskolin treatment potentiated the PAKc and
b-catenin level, either in the cytoplasm or in the nucleus,
evoked by Ex-4 (Figures 5A–5D). Moreover, Ex-4-stimu-
lated Ser675 phosphorylation and b-catenin nuclear accu-
mulation were inhibited by either the GLP-1R antagonist
Ex(9–39), the PKA inhibitor H89, or the shRNA-GLP-1R
(Figures 5A–5D). Furthermore, the co-immunoprecipita-
tion assay revealed that Ex-4 promoted the physical inter-
action between PKA and b-catenin (Figure 5E). We further
explored the direct interaction between GLP-1R/PKA
signaling and the phosphoinositide 3-kinase (PI3K)/AKT/
b-catenin signaling pathway. Our results showed that the
increase in PKAc induced by Ex-4 was associated with the
phosphorylation of PI3K and its downstream target AKT,
as well as with a decrease of phospho-glycogen synthase ki-
nase 3b (p-GSK3b) (Ser9) and an increase of b-catenin accu-
mulation in the cytoplasm and nucleus (Figures 5F–5L).
Treatment with wortmannin, a PI3K inhibitor, inhibited
the Ex-4-induced increases of pPI3K and p-AKT, increased
the level of p-GSK3b, and abrogated the cytoplasmic and
nuclear accumulation of b-catenin (Figures 5F and 5H–
5L). However, wortmannin did not significantly suppress
PKAc (Figure 5G).We next verified the association between
PKA and PI3K through a co-immunoprecipitation assay in
BMSCs using anti-PKA phosphosubstrate antibody fol-
lowed by immunoblotting for PI3K. As shown in Figure 5M,
PKA decreased PI3K in Ex-4-treated cells, indicating that
Ex-4 facilitated the physical interaction between PKA and
PI3K. In addition, Wnt3a, a prototypic Wnt ligand of the
frizzled receptor, only increased the nuclear accumulation
of b-catenin, but did not affect PKAc in BMSCs compared
with the effects of Ex-4 on the induction of PKA and b-cat-
enin. Moreover, Ex-4 stimulation of b-catenin nuclear
accumulation was potentiated by the addition of Wnt3a
(Figures 5N–5P). In contrast, Dickkopf 1 (DKK1), a Wnt
signaling pathway inhibitor, did not inhibit the accumula-
tion of b-catenin in the nucleus evoked by Ex-4 (Figures 5N
and 5P). The knockdown of b-catenin by shRNA in BMSCs
abolished Ex-4 stimulation of b-catenin accumulation in
the nucleus of BMSCs, but did not affect Ex-4-induced
PKA induction (Figures 5N–5P).
b-Catenin Regulated BMSC Differentiation through
GLP-1R
To further confirm the key role of b-catenin in the modu-
lating effect of GLP-1R on BMSC differentiation, we also
explored the effect of silencing b-catenin in BMSCs. Our re-
sults showed that the effect of Ex-4 on Runx2, Pparg, Balp,
and lpl expression was abolished when BMSCs were in-
fected with shRNA19538 and shRNA19539, but not with
shRNA19537 (Figure S3). Moreover, shRNA19538-medi-
ated downregulation of b-catenin in BMSCs inhibited thers
Figure 5. GLP-1R Activation Stimulated Wnt/b-Catenin Signaling in BMSCs
(A–D) Western blot of catalytic PKA (PKAc), phosphorylated b-catenin (b-cat Ser675), and nuclear b-catenin (N-b-cat) proteins in BMSCs
under different treatments. In (B)–(D) bars represent the quantification of catalytic PKA, b-cat Ser675, and nuclear b-catenin protein
normalized by b-actin or histone H3.1.
(E) Immunoprecipitation and western blot of the interaction between PKA and b-catenin in BMSCs cytoplasm after Ex-4 treatment.
(F) Western blot of PKAc, phospho-PI3K (p-PI3K), phospho-AKT (p-AKT), phospho-GSK3b (p-GSK3b), C-b-cat, or N-b-cat proteins in
BMSCs after treatment with Ex-4 or Ex-4 plus wortmannin (PI3K inhibitor).
(legend continued on next page)
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expression of osteoblast differentiation and maturation
markers such as Runx2/RUNX2, Sp7/osterix, Balp, and
Bglap, and significantly reduced the mineralization evoked
by Ex-4 (Figures 6A, 6B, 6D, 6E, 6G, 6H, 6J, and 6L). On the
other hand, the inhibition of the adipocyte differentiation
and lipid production in BMSCs mediated by Ex-4 was
reversed by b-catenin downregulation (Figures 6C, 6F, 6I,
6K, and 6M). All the Ex-4-induced functions on BMSCs,
such as induction of the markers related to osteoblast dif-
ferentiation, BMSC mineralization, and the repression of
the markers related to adipocyte differentiation, were not
affected by DKK1 treatment (Figure 6), suggesting that
DKK1 did not affect Ex-4-mediated increase of nuclear
b-catenin via the GLP-1R/PKA pathway.DISCUSSION
The present study analyzed and described the link between
GLP-1R and the Wnt/b-catenin signaling pathway in
BMSCs, in which GLP-1R receptor crosstalks with the
canonical Wnt/b-catenin pathway to promote bone for-
mation. Our results demonstrated that GLP-1R, mainly
expressed on BMSCs, promoted BMSC osteoblast differen-
tiation and inhibited their differentiation into adipocytes,
leading to the anabolic bone formation and amelioration
of osteoporosis in hindlimb-unloading rats. The mecha-
nisms of GLP-1R-mediated osteogenic action is exerted by
a dual role: through the cAMP/PKA/b-catenin/T cell factor
(TCF) pathway to initiate osteoblast differentiation, and
through the PKA/PI3K/Akt/GSK3b pathway to inhibit
b-catenin degradation and promote its nuclear accumula-
tion in BMSCs, which thereafter resulted in the anabolic
bone formation.
The gut-derived hormones, such as serotonin, peptide YY
(PYY), and incretins, are now recognized as critical regula-
tors in bone homeostasis (Dicembrini et al., 2012; Wong
et al., 2012; Yadav et al., 2008), since they display a negative
relationship with osteoblast activity. Therefore, these
results provide evidence that the inhibition of the biosyn-
thesis of gut-derived serotonin and PYY could become an
effective method to treat low-bone-mass diseases such as
osteoporosis.
In contrast to the negative regulation of serotonin and
PYY on bone homeostasis, our study demonstrated that
GLP-1R displayed a positive correlation with osteoblast ac-(G–L) Bars represent the quantification of PKAc, p-PI3K, p-AKT, p-GS
(M) Immunoprecipitation and western blot of the interaction betwee
(N) Western blot of catalytic PKA (PKAc) and nuclear b-catenin (N-b
(O and P) Bars represent the quantification of catalytic PKA and nucl
BMSCs were cultured in OIM. Data are expressed as mean ± SD from th
(Con) and ##p < 0.01 versus Ex-4 treatment by one-way ANOVA follow
586 Stem Cell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authotivity and bone growth. The treatment with the GLP-1R
agonist Ex-4 resulted in a significant increase in bone
mass in the hindlimb-unloading rats, associated with the
increase in osteoblast number and serum level of bone for-
mation biomarkers, with a parallel decrease in the adipo-
cyte number. In addition, the treatment with Ex-4 lowered
the increased rates of bone resorption biomarkers (Fig-
ure S4). These findings strongly indicated that Ex-4 pre-
vented osteopenia by promoting bone formation and
suppressing bone resorption. The effect of Ex-4 in the
control of bone resorption is exerted through a calci-
tonin-dependent pathway (Yamada et al., 2008). However,
GLP-1Rs are not present in osteoblasts, so GLP-1 cannot
exert a direct effect on them (Bollag et al., 2000; Yamada
et al., 2008). Therefore, the anabolic effects of Ex-4 on
bone formation that we observed were not a consequence
of a direct action on osteoblasts. As it is well known that os-
teoblasts and adipocytes both differentiate from common
mesenchymal precursor cells (Park et al., 2012), we specu-
lated that the changes in the osteoblast and adipocyte
numbers might be due to BMSC differentiation preferably
to adipocytes rather than osteoblasts, leading to bone for-
mation reduction and consequent osteopenia develop-
ment, while GLP-1R is expressed in human BMSCs to
promote cellular proliferation and prevent the differentia-
tion of human MSCs into adipocytes (Sanz et al., 2010).
Thus, we hypothesized that BMSC GLP-1R might play a
regulatory role in cell fate, resulting in osteoblast differen-
tiation rather than adipocyte differentiation. To test this
hypothesis, we investigated the roles of GLP-1R on BMSC
differentiation. BMSC GLP-1R activation by Ex-4 signifi-
cantly enhanced the expression of osteoblastogenic bio-
markers, thus promoting osteoblastic mineralization, and
inhibited the induction of adipocyte differentiation bio-
markers, thus decreasing endogenous lipoid deposits in
cells. GLP-1R silencing or block through its antagonists
reduced the effects described above. Taken together, these
results suggested that GLP-1R is involved in BMSC differen-
tiation into osteoblasts.
Recent studies indicate that the canonical Wnt pathway
affects BMSC osteogenic differentiation.Wnt signaling can
promote osteoblastic precursor differentiation into more
differentiated osteoblasts and can serve as a negative regu-
lator of adipogenesis (Glass et al., 2005; Krishnan et al.,
2006). This differentiation process is tightly regulated by
complex signaling events (Luu et al., 2007). b-Catenin isK3b, C-b-catenin, and N-b-cat proteins normalized by b-actin.
n PKA and PI3K in BMSC cytoplasm after Ex-4 treatment.
-cat) proteins in BMSCs after different treatments.
ear b-catenin protein normalized by b-actin or histone H3.1.
ree independent experiments. **p < 0.01 versus vehicle treatment
ed by a Student-Newman-Keuls t test.
rs
Figure 6. b-Catenin Silencing Abolished Ex-4 Regulatory Effects on BMSC Differentiation
(A–C) Real-time PCR of Runx2, Sp7, and PpargmRNA in BMSCs subjected to different treatments. Runx2 and Sp7mRNA expression in BMSCs
cultured in OIM were examined at days 7 and 10 after treatment, respectively. Pparg mRNA expression in BMSCs cultured in AIM was
examined at day 3 after treatment.
(D–F) Western blot of RUNX2, osterix and PPARg proteins in BMSCs subjected to different treatments. RUNX2 and osterix protein
expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. PPARg protein expression in BMSCs
cultured in AIM was examined at day 3 after treatment. Bars represent the protein quantitative data normalized by b-actin.
(G–I) Real-time PCR of Balp, Bglap, and Lpl mRNA in BMSCs subjected to different treatments. Balp and Bglap mRNA expression in BMSCs
cultured in OIM were examined at days 14 and 28 after treatment, respectively. Lpl mRNA expression in BMSCs cultured in AIM was
examined at day 14 after treatment.
(legend continued on next page)
Stem Cell Reports j Vol. 6 j 579–591 j April 12, 2016 j ª2016 The Authors 587
indeed a key signaling molecule that promotes cell
differentiation. Our results showed that Ex-4 dramatically
promoted b-catenin nuclear translocation and TCF7L2
expression in BMSCs. These effects were significantly in-
hibited by the block or knockdown of GLP-1R, suggesting
that GLP-1R was involved in crosstalk with the b-catenin
signaling pathway.
GLP-1R is localized in multiple tissues and cell types
(Holst, 2007). GLP-1 agonist binding to GLP-1R activates
various different pathways involved in the proliferation,
differentiation, and protection from apoptosis. On the ba-
sis of our present results we concluded that PKA, a GLP-1R
downstream effector exerting a strong bond to b-catenin
and PI3K and induced by Ex-4, played a dual role in its
interaction with the Wnt/b-catenin signaling pathway.
First, at the molecular level, PKA phosphorylated b-cate-
nin at its Ser675 and promoted b-catenin nuclear translo-
cation, and subsequently recruited LEF/TCF DNA binding
factors to initiate the expression of osteoblast differentia-
tion-related gene, driving BMSC differentiation into oste-
oblasts. It has also been reported that PKA phosphorylates
b-catenin at two sites, Ser552 and Ser675, thus preventing
its ubiquitination and thereby stabilizing b-catenin (Hino
et al., 2005; Taurin et al., 2006). Second, PKA also phos-
phorylated PI3K, which in turn phosphorylated AKT,
leading to GSK3b phosphorylation. GSK3b is a key
enzyme that negatively regulates the canonical Wnt/
b-catenin signaling pathway, and canonical Wnt signaling
activation also requires the inhibition of GSK3b activity
(Clevers and Nusse, 2012). The PKA signaling pathway
can crosstalk with the PI3K/AKT pathway in endothelial
cells (Namkoong et al., 2009), and the PI3K/AKT pathway
can communicate with the GSK3b/b-catenin pathway in
epithelial cells (Son et al., 2012). Phosphorylated GSK3b
dephosphorylates b-catenin and prevents its degradation
in the ubiquitin-dependent proteosome pathway. This
event also helps to promote b-catenin translocation into
the nucleus, leading to BMSC osteoblast differentiation.
In summary, our results indicated that BMSC GLP-1R
plays a crucial role in the regulation of osteoblast differen-
tiation by interacting with the PKA/b-catenin and PKA/
PI3K/AKT/GSK3b/b-catenin signaling pathways, both rep-
resenting critical events in Ex-4-induced anabolic bone
formation (Figure 7).(J and L) Mineralized matrix visualized in BMSCs and its quantification.
after treatment. Scale bar, 3 mm.
(K and M) Lipid accumulation in BMSCs and its quantification. BMSC
treatment. Scale bar, 50 mm.
BMSCs were treated with vehicle (Con), 10 nM Ex-4 alone (Ex-4), 10 nM
by sh-b-catenin were treated with 10 nM Ex-4 alone (Ex-4+sh-b-cat)
pendent experiments. **p < 0.01 versus vehicle treatment (Con) and
Student-Newman-Keuls t test.
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Animal Experiments
All experiments and animal care procedures were performed in
accordance with the recommendations and guidelines of the NIH
and were approved by the Animal Care and Use Committee of the
Fourth Military Medical University (Xi’an, China). The rat tail sus-
pension was performed for 28 days as previously described (Morey-
Holton and Globus, 2002). Ex-4 (GL Biochem), 4.2 mg/kg/day, was
intraperitoneally administered to the rats of the hindlimb-unload-
ing treatment group for 28 days, while the rats belonging to the
hindlimb-unloading control group received an intraperitoneal in-
jection of the same amount of normal saline for the same number
of days. The Ex-4 dose used was chosen according to our previous
experiment (Ma et al., 2013). Femurs and lumbar vertebrae (L3–L4)
were removed and stored at 80C for microCT analysis and bio-
mechanical testing. The femurs and vertebrae were subjected to a
three-point bending test and axial compression analysis using a
servo-hydraulic materials testing machine (MTS 858 Mini Bionix
II; MTS Systems) to perform a biomechanical analysis. Serum bone
formation markers were measured by commercially available ELISA
kits. Bone static histomorphometrymeasurements and bone histol-
ogy of the trabecular bone were performed as described in Supple-
mental Experimental Procedures.Cell Experiments
BMSCswere isolated from the femurs and tibias of 2- to 3-week-old
Sprague-Dawley male rats (Animal Center of Fourth Military Med-
ical University). The BMSCs derived from the second to the fourth
passages were used in all the experiments, at least three different
batches per experiment were used, and each experiment was per-
formed in triplicate. BMSC induction was performed using osteo-
genic or adipogenic induction medium in all experiments. The
BMSCs were cultured in OIM containing minimal essential
medium a (a-MEM), 10% fetal bovine serum (FBS), 100 U/ml
penicillin, 100 mg/ml streptomycin, 50 mg/l ascorbic acid
(Sigma-Aldrich), 10 nM dexamethasone (Sigma-Aldrich), and
10 mM b-glycerophosphate (Sigma-Aldrich) to induce osteogenic
differentiation, while they were cultured in AIM containing
a-MEM, 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin,
5 mg/ml insulin (Sigma-Aldrich), 1 mM dexamethasone (Sigma-Al-
drich), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich),
and 100 mM indomethacin (Sigma-Aldrich) to induce adipogenic
differentiation. BMSC GLP-1R and b-catenin were knocked down
by lentivirus transduction encoding shRNA. The osteogenic po-
tential was confirmed by mineralization assay and the adipogenic
potential was confirmed through oil red O staining. QuantitativeBMSCs were cultured in OIM and stained with alizarin red S at day 28
s were cultured in AIM and stained with oil red O at day 21 after
Ex-4 plus 0.5 mg/ml DKK1 (Ex-4+DKK1); b-catenin silenced BMSCs
in OIM or AIM. Data are expressed as mean ± SD from three inde-
##p < 0.01 versus Ex-4 treatment by one-way ANOVA followed by a
rs
Figure 7. Model Representing the GLP-1R
Role on Promoting BMSCs Osteoblast
Differentiation and Suppressing Their
Differentiation into Adipocytes through
Crosstalk with b-Catenin Signaling
Pathway
GLP-1 agonist, GLP-1, or Ex-4 bound to
GLP-1R activates the adenylyl cyclase with a
consequent production of cyclic AMP and
subsequent activation of PKA. GLP-1-medi-
ated activation of PKA results in b-catenin
phosphorylation on Ser675, leading to its
nuclear translocation and initiation of the
osteogenic gene expression. The activated
PKA also phosphorylates PI3K, leading to
the activation of AKT. Phosphorylated
PKA subsequently phosphorylates GSK3b,
resulting in the inhibition of GSK3b activity.
b-Catenin degradation mediated by GSK3b is
thus inhibited and nuclear accumulation of
b-catenin is potentiated. Finally, BMSC
osteoblast differentiation takes place and
anabolic bone formation is promoted.real-time PCR,western blot analysis, co-immunoprecipitation, and
confocal microscopy detection were also performed (see Supple-
mental Experimental Procedures).
Statistical Analysis
Data were expressed as mean ± SD and analyzed using SPSS for
Windows version 15.0. Statistical significance was determined by
one-way ANOVA followed by post hocmultiple comparisons using
a Student-Newman-Keuls t test. A value of p < 0.05 was considered
statistically significant.
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